BiotechTube

olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimen

Phase 3UNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy

Conditions

Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy

Trial Timeline

Oct 1, 2020 → Mar 30, 2021

NCT ID
NCT04536558

About olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimen

olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimen is a phase 3 stage product being developed by Sun Pharmaceutical for Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy. The current trial status is unknown. This product is registered under clinical trial identifier NCT04536558. Target conditions include Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy.

What happened to similar drugs?

5 of 12 similar drugs in Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy were approved

Approved (5) Terminated (2) Active (7)
✅DurvalumabAstraZenecaApproved
✅ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zetaRocheApproved
✅denosumab + pamidronateAmgenApproved
✅Sacituzumab Govitecan-hiyGilead SciencesApproved
✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved
🔄MEDI4736 (Durvalumab) + MEDI4736 (Durvalumab) + TremelimumabAstraZenecaPhase 3
🔄Pembrolizumab + Standard of Care (SOC) + Lenvatinib + Olaparib + MK-4280 + MK-4280AMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04536558Phase 3UNKNOWN

Competing Products

20 competing products in Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy

See all competitors
ProductCompanyStageHype Score
ALG.APV-527Alligator Bioscience ABPhase 1/2
18
ATOR-1017Alligator Bioscience ABPhase 1
19
ATOR-1015Alligator Bioscience ABPhase 1
19
mRNA-4359ModernaPhase 2
0
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
mRNA-2416ModernaPhase 2
0
E7050EisaiPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
18
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
RC220 + Doxorubicin (Adriamycin)Race OncologyPhase 1
30
BT1718Bicycle TherapeuticsPhase 1/2
22
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
19
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
26